Figure 5.

CBT-511 treatment reduced LoVo, human colorectal cancer (CRC) cell-line induced tumor xenograft growth. (A) LoVo, human CRC cells were injected subcutaneously into NOD Scid gamma (NSG™) mice and the tumors were allowed to grow. On days 7, 14, and 21 post-cell implantations, the mice were injected intravenous (i.v.) with either Doublecortin-like kinase 1 (DCLK1) CAR-T or mock CAR-T cells (1 × 10⁷ cells/mice). Tumor volumes were measured and all the mice were weighted during the experiment period. (B) CBT-511 treatment resulted in a significant (* p = 0.02) decreased tumor xenograft growth compared to treatment with mock CAR-T cells. The mice treated with CBT-511 had smaller tumors compared to mock CAR-T treated mice. (C) There were no significant differences in the animal weights between CBT-511 and mock CAR-T treated mice.